ORTHOPEDIATRICS CORP
For the period ended Sep 30, 2026. Filed Oct 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 28, 2026
KIDS$33.48-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows -
(Unaudited) (In Thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(23,780) | $(29,545) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Goodwill and other intangible asset impairments | 611 | 4,163 |
| Depreciation and amortization | 17,048 | 15,517 |
| Stock-based compensation | 12,592 | 13,362 |
| Fair value adjustment of contingent consideration | (814) | — |
| Accretion of acquisition installment payable | 365 | 105 |
| Deferred income taxes | (393) | 120 |
| Non-cash other | 695 | (88) |
| Changes in certain operating assets and liabilities: | ||
| Accounts receivable - trade | (4,717) | (8,270) |
| Inventories | (4,922) | (7,893) |
| Prepaid expenses and other current assets | (579) | 176 |
| Accounts payable - trade | 5,299 | (1,961) |
| Accrued expenses and other liabilities | 1,816 | 790 |
| Other | (1,074) | (1,675) |
| Net cash provided by (used in) operating activities | 2,147 | (15,199) |
| INVESTING ACTIVITIES | ||
| Other acquisitions, including clinics, net of cash acquired | (8,410) | (8,852) |
| Sale of short-term marketable securities | 15,000 | — |
| Investment in private companies and purchases of licenses | (810) | (2,007) |
| Purchase of short-term marketable securities | — | (15,000) |
| Purchases of property and equipment | (8,716) | (10,511) |
| Net cash used in investing activities | (2,936) | (36,370) |
| FINANCING ACTIVITIES | ||
| Proceeds from issuance of debt | — | 25,000 |
| Payment on debt issuance costs | (289) | — |
| Payments on mortgage notes | (127) | (119) |
| Payments on acquisition notes | (2,464) | (489) |
| Net cash (used in) provided by financing activities | (2,880) | 24,392 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (100) | 284 |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (3,769) | (26,893) |
| Cash, cash equivalents and restricted cash, beginning of year | $21,620 | $45,777 |
| Cash, cash equivalents and restricted cash, end of period | $17,851 | $18,884 |
| 2026 | 2025 | |
|---|---|---|
| SUPPLEMENTAL DISCLOSURES | ||
| Cash paid for interest | $5,646 | $4,562 |
| Transfer of instruments between property and equipment and inventory | $2,611 | $1,881 |
| Right-of-use assets obtained in exchange for lease liabilities | $2,838 | $4,812 |
| Issuance of common shares to settle an obligation with a vendor | $— | $1,261 |
| Issuance of common shares for MedTech installment | $2,398 | $226 |
| Issuance of common shares in connection with acquisitions | $1,656 | $— |
| Issuance of common shares in connection with Boston O&P acquisition | $— | $233 |
| Capital contribution associated with reclassification of MedTech liability to equity | $— | $2,062 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.